This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Empagliflozin with linagliptin oral


Oral formulations of empagliflozin with linagliptin.

Drugs List

  • empagliflozin 10mg and linagliptin 5mg tablets
  • empagliflozin 25mg and linagliptin 5mg tablets
  • GLYXAMBI 10mg+5mg tablets
  • GLYXAMBI 25mg+5mg tablets
  • Therapeutic Indications


    Oral combination treatment of type 2 diabetes

    Indicated in adults with type 2 diabetes mellitus:
    - To achieve better glycaemic control when the combination treatment with metformin and/or sulfonylurea and either empagliflozin or linagliptin does not adequately control blood glucose level.
    - When the treatment with combination of empagliflozin and linagliptin in separate dosage forms has been initiated.



    Initial dose: 1 tablet (10mg/5mg) once a day.
    Increase if necessary to 1 tablet (25mg/5mg) once a day.

    Patients with Renal Impairment

    Creatinine clearance equal to or greater than 60ml/minute
    No dose adjustment required.

    Creatinine clearance below 60ml/minute
    Treatment should not be initiated.

    Creatinine clearance falls persistently below 60ml/minute
    The dose should be adjusted to or maintained at a maximum daily dose of 10mg empagliflozin and 5mg linagliptin.

    Creatinine clearance of less than 45ml/minute
    Treatment should be discontinued.

    Additional Dosage Information

    Missed doses
    If a dose is missed and it is 12 hours or more until the next dose, it should be taken as soon as possible. The next dose should be taken at the usual time.
    If a dose is missed with less than 12 hours until the next dose, the dose should be skipped and the next dose taken at the usual time.

    Combination with sulfonylurea or insulin
    A lower dose of the sulfonylurea or insulin may be necessary to reduce the risk of hypoglycaemia.


    Children under 18 years
    Patients over 75 years at initiation
    Renal impairment - creatinine clearance below 60ml/minute at baseline
    Severe hepatic impairment

    Precautions and Warnings

    Acute illness
    Major surgery
    Predisposition to hypotension
    Cardiovascular disorder
    History of alcohol abuse
    History of pancreatitis
    Renal impairment - creatinine clearance 45 - 60ml/minute
    Urinary tract infection

    Reduce dose in patients with creatinine clearance below 60ml/min
    Advise ability to drive/operate machinery may be affected by side effects
    Exclude volume depletion before commencing treatment
    Contains mannitol
    Monitor renal function prior to initiating treatment
    Electrolyte & volume depletion may occur - interrupt treatment as necessary
    Hospitalised patients: Monitor blood ketones before restart treatment
    Monitor blood pressure
    Monitor renal function annually in patients with normal renal function
    Advise patient to report genital/perineal symptoms with fever or malaise
    Advise patient to report symptoms of diabetic ketoacidosis immediately
    Advise patients to report symptoms of acute pancreatitis immediately
    Discontinue if pemphigus-type reactions develop
    Discontinue SGLT2 inhibitor if Fournier's gangrene is suspected
    Interrupt treatment temporarily in complicated urinary tract infections
    Test results for urinary glucose will be positive
    Discontinue if creatinine clearance below 45ml/minute
    Discontinue if pancreatitis is suspected
    Do not restart treatment following confirmation of pancreatitis
    Interrupt therapy if acute serious illness requiring hospitalisation occurs
    Interrupt treatment in patients undergoing major surgery
    Pregnancy confirmed: Discontinue this medication
    Discontinue if diabetic ketoacidosis is suspected
    Advise patient not to take St John's wort concurrently
    Advise patient on the need for adequate foot hygiene
    Patient to inform DVLA if fitness to drive impaired or hypoglycaemic risk

    Cases of diabetic ketoacidosis (DKA) have been reported in patient taking sodium-glucose co-transporter-2 (SGLT2) inhibitors. The signs and symptoms of DKA are rapid weight loss; feeling or being sick; stomach pain; fast and deep breathing; sleepiness; a sweet smell to the breath; a sweet or metallic taste in the mouth; or a different odour to urine or sweat. The risk factors for DKA include low beta cell function reserve; conditions leading to restricted food intake or severe dehydration; sudden reduction in insulin; increased insulin requirements due to acute illness; surgery and alcohol abuse.
    Restarting treatment in patients with previous DKA while on SGLT2 inhibitor is not recommended, unless another precipitating factor has been identified and resolved.

    Clinical trials suggest there is an increased risk of lower limb amputation in patients treated with another SGLT2 inhibitor. An increased risk of amputation has not yet been seen in studies of empagliflozin. However, the increased risk of amputation cannot be excluded and caution should be advised in patients receiving empagliflozin with linagliptin.

    Cases of necrotising fasciitis of the perineum (Fournier's gangrene) have been reported in patients taking SGLT2 inhibitors. Urgent surgical intervention and antibiotics may be necessary. Patients should seek medical attention if symptoms of pain, tenderness, erythema, or swelling in the genital or perineal area, accompanied by fever or malaise arise.

    If bullous pemphigoid is suspected, empagliflozin with linagliptin should be discontinued.

    Pregnancy and Lactation


    Empagliflozin with linagliptin is contraindicated in pregnancy.

    The manufacturer advises avoiding empagliflozin with linagliptin during pregnancy.

    Animal studies have indicated empagliflozin with linagliptin crosses the placenta during late gestation but does not indicate harmful effects regarding early embryonic development. Studies with empagliflozin in animals have shown adverse effects on postnatal development.

    Detailed guidance on the treatment of diabetes during pregnancy is available from the National Institute for Health and Clinical Excellence (NICE) at


    Empagliflozin with linagliptin is contraindicated in breastfeeding.

    The manufacturer does not recommend breastfeeding whilst taking empagliflozin with linagliptin.

    There is limited data regarding the excretion of empagliflozin with linagliptin into breast milk. Animal studies have shown excretion of empagliflozin and linagliptin into milk. A risk to newborns cannot be excluded.


    Advise patients to report symptoms of diabetic ketoacidosis immediately.

    Advise patients to report genital/perineal symptoms with fever or malaise.

    Advise patient to report symptoms of pancreatitis.

    Advise patients on the need for adequate foot hygiene.

    Advise ability to drive/operate machinery may be affected by side effects.

    Advise patient to report to DVLA if there is a risk of hypoglycaemia, or if fitness to drive may be impaired due to diabetes complications. Guidance can be found by accessing website.

    Side Effects

    Bullous pemphigoid
    Decrease in glomerular filtration rate
    Diabetic ketoacidosis
    Elevated serum lipase
    Fournier's gangrene
    Genital infections
    Genital moniliasis
    Hypersensitivity reactions
    Increase in haematocrit
    Increased amylase secretion
    Increased urination
    Mouth ulcers
    Rise in blood lipids
    Serum creatinine increased
    Urinary tract infections

    Effects on Laboratory Tests

    Patients will test positive for glucose in their urine due to the mechanism of action.

    Interference with 1,5-anhydroglucitol (1,5-AG) assay
    Monitoring glycaemic control with 1,5-AG assay is not recommended due to unreliable measurements of 1,5-AG in patients taking SGLT2 inhibitors. Alternative methods to monitor glycaemic control is advised.


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2022

    Reference Sources

    Summary of Product Characteristics: Glyxambi 10mg/5mg and 25mg/5mg film-coated tablets. Boehringer Ingelheim Ltd. Revised July 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.